Kanishk Kumar: Thalassemia Pipeline 2025 Addressing Hemoglobin Deficiencies in Inherited Blood Disorders
Kanishk Kumar, Digital Marketing Executive at DelveInsight Business Research LLP, shared a post on LinkedIn:
”Thalassemia Pipeline 2025: Addressing Hemoglobin Deficiencies in Inherited Blood Disorders
Thalassemia, a group of inherited blood disorders causing reduced hemoglobin synthesis and chronic anemia, is advancing with innovative therapies in 2025. The Thalassemia Pipeline features 25+ pharmaceutical firms developing 28+ investigational medications, from gene editing to small molecules, aimed at increasing hemoglobin levels, reducing transfusion dependency, and improving quality of life for patients with varying severity.
Key Developments in Thalassemia Treatment:
Etavopivat by Novo Nordisk, a PKR activator in Phase III, aims to improve red blood cell health and reduce anemia in thalassemia by enhancing oxygen affinity and decreasing hemolysis.
CS-101 by Correct Sequence Therapeutics, a gene editing therapy in Phase I, reactivates fetal hemoglobin production for a potential lifetime cure using the patient’s own stem cells.
Leading Thalassemia Companies include Novo Nordisk , Kind Pharmaceuticals LLC, Correct Sequence Therapeutics , Editas Medicine, San Rocco Therapeutics, Lantu Biopharma, Regeneron , Kanglin Biotec, Shanghai BDgene Co., Ltd., BioRay Pharmaceutical , Celgene, Mabwell , among others.
Promising therapies include Etavopivat, AND017, CS101, among others.
DelveInsight’s comprehensive report on the Thalassemia Pipeline Analysis 2025․՛՛
Stay updated with Hemostasis Today.
-
May 24, 2026, 17:48Flora Peyvandi: Crucial Role of Placental ADAMTS13 in Perinatal Survival
-
May 24, 2026, 17:13Mahtab Mashayekhi: The Evolving Role of Red Blood Cell Exchange in the Management of SCD
-
May 24, 2026, 17:12Silvina Graña: Helping Families Better Understand Hemophilia and Daily Life With Bleeding Disorders
-
May 24, 2026, 17:11Miikka Vikkula: Key Insights from the ISSVA 2026 World Congress
-
May 24, 2026, 17:10Mathieu Jackson: Proud to Be Present at This Historic Moment for the Global Bleeding Disorders Community
-
May 24, 2026, 17:09Ramina Fazeli: Highlighting the Emerging Role of Neutrophil Extracellular Traps in Ovarian Cancer
-
May 24, 2026, 16:12William Wallace: Normal B12 Levels May Still Cause Brain Damage and Cognitive Decline
-
May 24, 2026, 15:54Marc Carrier: Ottawa Race Weekend Raised Over 7,000 USD for Thrombosis Canada
-
May 24, 2026, 15:44Janak Sadhu: Building a Stroke-Free Mehsana Through Community Awareness and Healthcare Collaboration